Study protocol for the multicentre cohorts of Zika virus infection in pregnant women, infants, and acute clinical cases in Latin America and the Caribbean: The ZIKAlliance consortium

Background: The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites were selected over a wide geographic range within Latin America and the Caribbean, taking into account the dynamic course of the ZIKV epidemic. Methods: Recruitment to the PW cohort will take place in antenatal care clinics. PW will be enrolled regardless of symptoms and followed over the course of pregnancy, approximately every 4 weeks. PW will be revisited at delivery (or after miscarriage/abortion) to assess birth outcomes, including microcephaly and other congenital abnormalities according to the evolving definition of congenital Zika syndrome (CZS). After birth, children will be followed for 2 years in the CH cohort. Follow-up visits are scheduled at ages 1-3, 4-6, 12, and 24 months to assess neurocognitive and developmental milestones. In addition, a NH cohort for the characterization of symptomatic rash/fever illness was designed, including follow-up to capture persisting health problems. Blood, urine, and other biological materials will be collected, and tested for ZIKV and other relevant arboviral diseases (dengue, chikungunya, yellow fever) using RT-PCR or serological methods. A virtual, decentralized biobank will be created. Reciprocal clinical monitoring has been established between partner sites. Substudies of ZIKV seroprevalence, transmissio

Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum

AUTORES: Irene Bosch,1,2* Helena de Puig,1,3* Megan Hiley,1 Marc Carré-Camps,1,4 Federico Perdomo-Celis,5 Carlos F. Narváez,5 Doris M. Salgado,5 Dewahar Senthoor,1 Madeline O’Grady,1 Elizabeth Phillips,1 Ann Durbin,1,6 Diana Fandos,1,4 Hikaru Miyazaki,1 Chun-Wan Yen,1 Margarita Gélvez-Ramírez,7 Rajas V. Warke,8 Lucas S. Ribeiro,9 Mauro M. Teixeira,9 Roque P. Almeida,10 José E. Muñóz-Medina,11 Juan E. Ludert,12 Mauricio L. Nogueira,13 Tatiana E. Colombo,13 Ana C. B. Terzian,13 Patricia T. Bozza,14 Andrea S. Calheiros,14 Yasmine R. Vieira,15 Giselle Barbosa-Lima,15 Alexandre Vizzoni,15 José Cerbino-Neto,15 Fernando A. Bozza,15,16 Thiago M. L. Souza,14,17 Monique R. O. Trugilho,18 Ana M. B. de Filippis,19 Patricia C. de Sequeira,19 Ernesto T. A. Marques,20,21 Tereza Magalhaes,20,22 Francisco J. Díaz,23 Berta N. Restrepo,24 Katerine Marín,24 Salim Mattar,25 Daniel Olson,26 Edwin J. Asturias,26 Mark Lucera,27 Mohit Singla,28 Guruprasad R. Medigeshi,29 Norma de Bosch,30 Justina Tam,1,31 Jose Gómez-Márquez,1 Charles Clavet,31 Luis Villar,7 Kimberly Hamad-Schifferli,3,32† Lee Gehrke1,33† --- INFORMAÇÃO DE AUTORES: 1Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.2Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. 3Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.4Institut Químic de Sarrià, Universitat Ramon Llull, Barcelona, Spain. 5Programa de Medicina, Facultad de Salud, Universidad Surcolombiana, Neiva, Colombia.6Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.7Universidad Industrial de Santander and AEDES Program (Alianza para el desarrollo de estrategias que disminuyan el impacto de enfermedades transmitidas por Aedes como resultado del estudio de sus endemias y epidemias), Bucaramanga, Santander, Colombia.8HiMedia Laboratories Pvt. Ltd.,Mumbai, India. 9Immunopharmacology Group, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte, Brazil. 10Departamento de Medicina Interna e Patologia, Hospital Universitário/Empresa Brasileira de ServiçosHospitalares (EBSERH),Universidade Federal de Sergipe,Aracaju, Brazil.11Laboratorio Central de Epidemiología, Instituto Mexicano del Seguro Social, Avenida Jacarandas S/N, Esquina Circuito Interior, Colonia La Raza Del Azcapotzalco, Códgio Postal 02990 México D.F., México. 12Departamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Ciudad de México, México. 13Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil.14Immunopharmacology Laboratory, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.15National Institute of Infectious Disease Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.16D’Or Institute of Research and Education (IDOR), Rio de Janeiro, Brazil.17National Institute for Science and Technology on Innovation onNeglectedDiseases (INCT/IDN), Center for TechnologicalDevelopment inHealth (CDTS), FIOCRUZ, Rio de Janeiro, Brazil. 18Toxinology Laboratory and Center for Technological Development in Health (CDTS), FIOCRUZ, Rio de Janeiro, Brazil.19Flavivirus Laboratory, FIOCRUZ, Rio de Janeiro, Brazil. 20AggeuMagalhães Research Center, FIOCRUZ, Pernambuco, Recife, Brazil.21Department of Infectious Disease and Microbiology, University of Pittsburgh, Pittsburgh, PA 15213, USA. 22Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.23Immunovirology Group, School of Medicine, University of Antioquia, Medellín, Colombia.24Instituto Colombiano de Medicina Tropical (ICMT), Universidad CES, Sabaneta, Antioquia, Colombia.25Universidad de Córdoba, Montería, Córdoba, Colombia.26Division of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA. 27Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.28Department of Paediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.29Translational Health Science and Technology Institute, Faridabad, India.30Universidad Central de Venezuela, Caracas, Venezuela. 31Winchester Engineering Analytical Center (WEAC), Winchester, MA01890, USA.32Department of Engineering, University of Massachusetts Boston, Boston, MA 02125, USA. 33Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA..Submitted by Sandra Infurna ([email protected]) on 2017-10-17T12:32:16Z No. of bitstreams: 1 ernesto_marques_etal_IOC_2017.pdf: 1660504 bytes, checksum: 2c70b690dd3275b474bf293855979894 (MD5)Approved for entry into archive by Sandra Infurna ([email protected]) on 2017-10-17T12:48:46Z (GMT) No. of bitstreams: 1 ernesto_marques_etal_IOC_2017.pdf: 1660504 bytes, checksum: 2c70b690dd3275b474bf293855979894 (MD5)Made available in DSpace on 2017-10-17T12:48:46Z (GMT). No. of bitstreams: 1 ernesto_marques_etal_IOC_2017.pdf: 1660504 bytes, checksum: 2c70b690dd3275b474bf293855979894 (MD5) Previous issue date: 2017Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ. Brasil.Múltipla - ver em Nota

Zika Virus Infection-Associated Acute Transient Polyneuritis

On behalf of the RIO-GBS-ZIKV Research GroupSubmitted by Sandra Infurna ([email protected]) on 2017-05-16T10:46:30Z No. of bitstreams: 1 anamaria_bispo_etal_IOC_2017.pdf: 161845 bytes, checksum: e12dd91309ae6c57809c98d33d77ce2f (MD5)Approved for entry into archive by Sandra Infurna ([email protected]) on 2017-05-16T11:03:32Z (GMT) No. of bitstreams: 1 anamaria_bispo_etal_IOC_2017.pdf: 161845 bytes, checksum: e12dd91309ae6c57809c98d33d77ce2f (MD5)Made available in DSpace on 2017-05-16T11:03:32Z (GMT). No. of bitstreams: 1 anamaria_bispo_etal_IOC_2017.pdf: 161845 bytes, checksum: e12dd91309ae6c57809c98d33d77ce2f (MD5) Previous issue date: 2017Universidade Federal Fluminense. Niterói, RJ, Brasil.Cleveland Clinic. Cardiovascular Center of Neurological Institute. Ohio, U|SA.Universidade Federal Fluminense. Niterói, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ. Brasil.Rush University Medical Center. Chicago, IL, USA.This article describes a case series of 3 patients admitted to a tertiary hospital in Rio de Janeiro during the 2016 outbreak of Zika virus infection in Brazil

Safety of the yellow fever vaccine in people living with HIV: a longitudinal study exploring post-vaccination viremia and hematological and liver kinetics

Background: Safety data on the yellow fever vaccine 17DD in People Living with HIV (PLWH) are limited. This study explored the occurrence of post-vaccination 17DD viremia and the kinetics of hematological and liver laboratorial parameters in PLWH and HIV-uninfected participants [HIV(-) controls]. Methods: We conducted a secondary analysis of a longitudinal interventional trial (NCT03132311) study that enrolled PLWH and HIV(-) controls to receive a single 17DD dose and were followed at 5, 30 and 365 days after vaccination in Rio de Janeiro, Brazil. 17DD viremia (obtained throughreal-time PCR and plaque forming units’ assays), hematological (neutrophils, lymphocytes and platelets counts) and liver enzymes (ALT and AST) results were assessed at baseline and Days 5 and 30 post-vaccination. Logistic regression models explored factors associated with the odds of having positive 17DD viremia. Linear regression models explored variables associated with hematological and liver enzymes results at Day 5. Results: A total of 202 PLWH with CD4 ≥ 200 cells/µL and 68 HIV(-) controls were included in the analyses. 17DD viremia was found in 20.0 % of the participants and was twice more frequent in PLWH than in HIV(-) controls (22.8% vs. 11.8 %, p-value < 0.001). Neutrophils, lymphocytes and platelets counts dropped at Day 5 and returned to baseline values at Day 30. 17DD viremia was associated with lower nadir of lymphocytes and platelets at Day 5. ALT levels did not increase post-vaccination and were not associated with 17DD viremia. Conclusions: 17DD was safe and well-tolerated in PLWH with CD4 ≥ 200 cells/µL. Post-vaccination viremia was more frequent in PLWH than in controls. Transient and self-limited decreases in lymphocytes and neutrophils occurred early after vaccination. 17DD viremia was associated with lower lymphocytes and platelets nadir after vaccination. We did not observe elevations in ALT after 17DD vaccination

Lineage-Specific Real-Time RT-PCR for Yellow Fever Virus Outbreak Surveillance, Brazil

The current yellow fever outbreak in Brazil prompted widespread yellow fever virus (YFV) vaccination campaigns, imposing a responsibility to distinguish between vaccine- and wild-type YFV-associated disease. We developed novel multiplex real-time reverse transcription PCRs that differentiate between vaccine and American wild-type YFV. We validated these highly specific and sensitive assays in an outbreak setting

External Quality Assessment for Zika Virus Molecular Diagnostic Testing, Brazil

We conducted an external quality assessment of Zika virus molecular diagnostic tests in Brazil using a new Zika virus standard. Of 15 laboratories, 73% showed limited sensitivity and specificity. Viral load estimates varied significantly. Continuous quality assurance is needed to adequately estimate risk for Zika virus-associated disease and determine patient care

Serological Evidence of Exposure to Saint Louis Encephalitis and West Nile Viruses in Horses of Rio de Janeiro, Brazil

Infections with arboviruses are reported worldwide. Saint Louis encephalitis (SLEV) and West Nile viruses (WNV) are closely related flaviviruses affecting humans and animals. SLEV has been sporadically detected in humans, and corresponding antibodies have been frequently detected in horses throughout Brazil. WNV was first reported in western Brazil over a decade ago, has been associated with neurological disorders in humans and equines and its prevalence is increasing nationwide. Herein, we investigated by molecular and serological methods the presence or evidence of SLEV and WNV in equines from Rio de Janeiro. A total of 435 serum samples were collected from healthy horses and tested for specific neutralizing antibodies by plaque reduction neutralization test (PRNT90). Additionally, serum and central nervous system samples from 72 horses, including horses with neurological disorders resulting in a fatal outcome or horses which had contact with them, were tested by real-time reverse transcription&ndash;polymerase chain reaction (RT-qPCR) for both viruses. Adopting the criterion of four-fold antibody titer difference, 89 (20.4%) horses presented neutralizing antibodies for SLEV and five (1.1%) for WNV. No evidence of SLEV and WNV infection was detected by RT-qPCR and, thus, such infection could not be confirmed in the additional samples. Our findings indicate that horses from Rio de Janeiro were exposed to both SLEV and WNV, contributing to the current knowledge on the distribution of these viruses flaviviruses in Brazil

Zika virus infection in pregnant women in Rio de Janeiro: preliminary report

Artigo liberado em acesso aberto como parte do acordo para tornar público todos os dados produzidos sobre o vírus zika - Compartilhamento de dados em emergências de saúde pública - http://www.wellcome.ac.uk/News/Media-office/Press-releases/2016/WTP060169.htmVersão final do artigo - handle https://www.arca.fiocruz.br/handle/icict/17780Submitted by Claudete Queiroz ([email protected]) on 2016-03-08T19:16:29Z No. of bitstreams: 1 Zika Virus Infection in Pregnant Women - preliminary report.pdf: 646105 bytes, checksum: 76b9427d455f2a5cbb1aa17b53e4cfc6 (MD5)Approved for entry into archive by Claudete Queiroz ([email protected]) on 2016-03-09T11:54:02Z (GMT) No. of bitstreams: 1 Zika Virus Infection in Pregnant Women - preliminary report.pdf: 646105 bytes, checksum: 76b9427d455f2a5cbb1aa17b53e4cfc6 (MD5)Made available in DSpace on 2016-03-09T11:54:02Z (GMT). No. of bitstreams: 1 Zika Virus Infection in Pregnant Women - preliminary report.pdf: 646105 bytes, checksum: 76b9427d455f2a5cbb1aa17b53e4cfc6 (MD5) Previous issue date: 2016Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Biomedical Research Institute of Southern California. Oceanside, California, EUA.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.David Geffen UCLA School of Medicine, Los Angeles, EUA.David Geffen UCLA School of Medicine, Los Angeles, EUA.David Geffen UCLA School of Medicine, Los Angeles, EUA.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.David Geffen UCLA School of Medicine, Los Angeles, EUA.BACKGROUND Zika virus (ZIKV) has been linked to neonatal microcephaly. To characterize the spectrum of ZIKV disease in pregnancy, we followed patients in Rio de Janeiro to describe clinical manifestations in mothers and repercussions of acute ZIKV infection in fetuses. METHODS We enrolled pregnant women in whom a rash had developed within the previous 5 days and tested blood and urine specimens for ZIKV by reverse-transcriptase–polymerasechain-reaction assays. We followed the women prospectively and collected clinical and ultrasonographic data. RESULTS A total of 88 women were enrolled from September 2015 through February 2016; of these 88 women, 72 (82%) tested positive for ZIKV in blood, urine, or both. The timing of acute ZIKV infection ranged from 5 to 38 weeks of gestation. Predominant clinical features included pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 28% had fever (short-term and low-grade).Women who were positive for ZIKV were more likely than those who were negative for the virus to have maculopapular rash (44% vs. 12%, P=0.02), conjunctival involvement (58% vs. 13%, P=0.002), and lymphadenopathy (40% vs. 7%, P=0.02). Fetal ultrasonography was performed in 42 ZIKV-positive women (58%) and in all ZIKV-negative women. Fetal abnormalities were detected by Doppler ultrasonography in 12 of the 42 ZIKV-positive women (29%) and in none of the 16 ZIKV-negative women. Adverse findings included fetal deaths at 36 and 38 weeks of gestation (2 fetuses), in utero growth restriction with or without microcephaly (5 fetuses), ventricular calcifications or other central nervous system (CNS) lesions (7 fetuses), and abnormal amniotic fluid volume or cerebral or umbilical artery flow (7 fetuses). To date, 8 of the 42 women in whom fetal ultrasonography was performed have delivered their babies, and the ultrasonographic findings have been confirmed. CONCLUSIONS Despite mild clinical symptoms, ZIKV infection during pregnancy appears to be associated with grave outcomes, including fetal death, placental insufficiency, fetal growth restriction, and CNS injury